Introduction {#s01}
============

Intrahepatic cholangiocarcinoma (ICC), a primary liver cancer, initially presents in the intrahepatic biliary tree and is the second most common liver malignancy after hepatocellular carcinoma, accounting for 10% of all primary liver cancers^[@b1]^. Surgical resection is currently the most effective treatment for ICC, but has several intrinsic limitations and disadvantages, such as poor curative effect, high recurrence rate, and low survival rate. The liver is the most common target organ for ICC metastasis, whereas lymph node metastasis (LNM) has been reported in 30%--70% of cases. Therefore, controlling LNM is the most important consideration for ICC treatment. For lymph node dissection (LND), there are various questions and controversies regarding the following aspects: when to perform LND, the extent of LND, and whether prophylactic LND should be performed. This study retrospectively analyzed the clinical data of 104 ICC cases collected from January 2008 to December 2013 at Tianjin Medical University Cancer Institute and Hospital. The clinical treatment strategies and prognostic factors for ICC were then explored.

Materials and methods {#s02}
=====================

General clinical data {#s02.01}
---------------------

A total of 148 ICC cases were admitted to our hospital from January 2008 to December 2013. We ruled out 44 cases, including 4 cases diagnosed as hepatocellular carcinoma (HCC), 13 cases without surgical and interventional therapy, and 27 cases that were not followed up. The final 104 cases were investigated and divided into the hepatic hilum lymphadenectomy (HLL; 21 cases, 20.19%), extended hepatic hilum lymphadenectomy (EHLL; 12 cases, 11.54%), and the non-lymphadenectomy (NL; 71 cases, 68.27%) groups.[**Table 1**](#Table1){ref-type="table"} shows the clinical features of the case groups.

###### 

Summary of clinicopathological features of ICC, *n* (%)

  Characteristics      HLL         EHLL         NL
  -------------------- ----------- ------------ ------------
  Gender                                        
  Female               12 (57.1)   8 (66.7)     27 (38.0)
  Male                 9 (42.9)    4 (33.3)     44 (62.0)
  Age, years                                    
  ≤60                  15 (71.4)   6 (50.0)     41 (57.7)
  \>60                 6 (28.6)    6 (50.0)     30 (42.3)
  Tumor number                                  
  Solitary             12 (57.1)   9 (75.0)     41 (57.7)
  Multiple             9 (42.9)    3 (25.0)     30 (42.3)
  Tumor diameter, cm                            
  ≤5                   6 (28.6)    4 (33.3)     40 (56.3)
  \>5                  15 (71.4)   8 (66.7)     31 (43.7)
  Hepatitis B                                   
  Negative             11 (52.4)   10 (83.3)    38 (53.5%)
  Positive             10 (47.6)   2 (16.7)     33 (46.5)
  Cirrhosis                                     
  Negative             16 (76.2)   12 (100.0)   39 (54.9)
  Positive             5 (23.8)    0 (0.0)      32 (45.1)
  Fer                                           
  Normal               6 (28.6)    6 (50.0)     41 (57.7)
  Higher               15 (71.4)   6 (50.0)     30 (42.3)
  CEA                                           
  Normal               13 (61.9)   8 (66.7)     62 (87.3)
  Higher               8 (38.1)    4 (33.3)     9 (12.7)
  CA19-9                                        
  Normal               5 (23.8)    2 (16.7)     48 (67.6)
  Higher               16 (76.2)   10 (83.3)    23 (32.4)
  AFP                                           
  Normal               20 (95.2)   11 (91.7)    50 (70.4)
  Higher               1 (4.8)     1 (8.3)      21 (29.6)
  AJCC stage                                    
  I/II                 10 (47.6)   9 (75.0)     49 (69.0)
  III/IVa/IVb          11 (52.4)   3 (25.0)     22 (31.0)
  Differentiation                               
  Poor                 7 (33.3)    7 (58.3)     40 (56.3)
  Well or moderate     14 (66.7)   5 (41.7)     31 (43.7)
  Vascular invasion                             
  Negative             13 (61.9)   8 (66.7)     48 (67.6)
  Positive             8 (38.1)    4 (33.3)     23 (32.4)
  LNM                                           
  Negative             15 (71.4)   7 (58.3)     71 (100.0)
  Positive             6 (28.6)    5 (41.7)     0 (0.0)

Therapeutic modalities {#s02.02}
----------------------

The tumor diameters of the 104 cases ranged from 1 cm to 15 cm. All the cases that underwent liver resection were pathologically confirmed as R0 resections. The excision areas of the HLL group included the gallbladder neck and any single or several lymph node areas in zones 12 (12A, 12B, and 12P), 5, 7, 8, and 9. The EHLL group further underwent extraction of any single or several areas of zone 13, peritoneal lymph nodes, and intestinal region, in addition to the excision areas of the HLL group. No case in the NL group underwent lymph node removal. Additionally, 43 cases underwent regular hepatic resection (monosegmentectomy), 22 cases underwent left hemihepatectomy, 24 cases underwent right hemihepatectomy, 5 cases underwent extended left hemihepatectomy, 6 cases underwent extended right hemihepatectomy, and 4 cases underwent liver wedge resection.

Follow up {#s02.03}
---------

The follow-up was performed via telephone conversations. The median follow-up duration was 41 months (1--92 months). The overall survival (OS) time was defined as the time from surgery to death or end of follow-up. The follow-up data of the 104 cases were completed.

Statistical analysis {#s02.04}
--------------------

Statistical analysis was conducted by SPSS 19.0 statistical software. Survival analysis was performed by the Kaplan-Meier method, and the prognostic factors were compared by the log-rank test. Independent ICC prognostic factors were analyzed by the Cox regression model. Clinical parameters included gender, age, hepatitis B status, cirrhosis, tumor number, American Joint Committee on Cancer (AJCC) stage, differentiation, maximum tumor diameter, tumor marker levels \[ferritin (Fer), alpha fetoprotein, CEA, and CA19-9\], vascular invasion, LNM, and lymph node excision. *P* \< 0.05 was considered as statistically significant.

Results {#s03}
=======

Survival rate {#s03.01}
-------------

The 1-, 2-, and 3-year OS rates of the 104 cases were 72.1%, 56.1%, and 43.7%, respectively. The median survival time was 34 months. The 1-, 2-, and 3-year OS rates of HLL were 42.9%, 28.6%, and 28.6%, respectively. The 1-, 2-, and 3-year OS rates of EHLL were 75.0%, 66.7%, and 33.3%, respectively. The 1-, 2-, and 3-year OS rates of NL were 78.9%, 62.5%, and 47.8%, respectively. The overall differences among the three groups were statistically significant. The 1-, 2-, and 3-year OS were significantly higher in the NL group than in the HLL group (*P* \< 0.05,[**Table 2**](#Table2){ref-type="table"}).

###### 

Comparison of the OS according to the LND

  LND    HLL             EHLL            NL                      
  ------ ------- ------- ------- ------- ------- ------- ------- -------
  HLL    \-      \-              2.855   0.091           6.345   0.012
  EHLL   2.855   0.091   \-      \-      0.002   0.969           
  NL     6.345   0.012   0.002   0.969   \-      \-              

###### 

Results of univariate analysis

  Characteristic       *n*   Survival rate (%)   *P*           
  -------------------- ----- ------------------- ------ ------ -------
  Gender                                                       0.028
  Female               47    68.1                44.0   31.1   
  Male                 57    75.4                66.0   53.2   
  Age, years                                                   0.041
  ≤60                  62    75.8                62.4   54.3   
  \>60                 42    66.7                46.7   27.6   
  Tumor number                                                 0.503
  Solitary             62    75.8                58.8   44.0   
  Multiple             42    66.7                52.4   43.7   
  Tumor diameter, cm                                           0.059
  ≤5                   50    76.0                60.9   53.7   
  \>5                  54    68.5                48.9   32.4   
  Hepatitis B                                                  0.896
  Negative             59    74.6                56.8   44.1   
  Positive             45    68.9                52.4   43.0   
  Liver cirrhosis                                              0.649
  Negative             67    71.6                56.2   44.7   
  Positive             37    73.0                52.6   41.4   
  Fer                                                          0.010
  Normal               53    83.0                67.2   55.9   
  Higher               51    60.8                42.0   31.5   
  CEA                                                          0.042
  Normal               83    75.9                60.6   46.5   
  Higher               21    57.1                38.1   31.7   
  CA-199                                                       0.038
  Normal               55    80.0                62.4   52.5   
  Higher               49    63.3                46.2   34.6   
  AFP                                                          0.632
  Normal               81    70.4                54.8   43.7   
  Higher               23    78.3                60.6   44.2   
  AJCC stage                                                   0.000
  I/II                 68    82.4                71.1   54.0   
  III/IVa/IVb          36    52.8                27.8   23.8   
  Differentiation                                              0.009
  Poor                 54    68.5                48.7   28.4   
  Well or moderate     50    76.0                63.6   59.9   
  Vascular invasion                                            0.689
  Negative             69    71.0                55.9   42.5   
  Positive             35    74.3                56.1   46.8   
  LNM                                                          0.003
  Negative             93    76.3                59.5   47.8   
  Positive             11    36.4                27.3   0      
  LND                                                          0.032
  HLL                  21    47.6                28.6   28.6   
  EHLL                 12    75.0                66.7   33.3   
  NL                   71    78.9                62.5   47.8   

Prognostic factors {#s03.02}
------------------

Univariate analysis ([**Table 3**](#Table3){ref-type="table"}) revealed that age, gender, AJCC stage, differentiation, tumor marker levels, LNM, and LND significantly affected the prognosis of ICC patients. Meanwhile, multivariate analysis ([**Table 4**](#Table4){ref-type="table"}) showed that age, AJCC stage, differentiation, Fer, and LNM were independent risk factors for survival. Furthermore, 62 of the 104 cases once received adjuvant therapy before or after surgery, including 37, 10, and 15 cases that received transcatheter arterial chemoembolization, radiofrequency ablation, and chemotherapy, respectively. After further analysis, we found that the 1-, 2-, and 3-year OS did not significantly differ between the adjuvant therapy (71.7%, 51.0%, and 38.6%, respectively) and non-adjuvant therapy groups (72.7%, 63.5%, and 51.2%, respectively). Therefore, the effects of adjuvant therapy can be excluded.

###### 

Results of multivariate analysis

  Clinical features   B          Wald     *P*      Exp (B)   Exp (B) 95% CI
  ------------------- ---------- -------- -------- --------- ----------------
  Age                 -- 0.607   4.841    \<0.05   0.545     (0.317, 0.936)
  AJCC stage          -- 0.948   11.510   \<0.05   0.388     (0.224, 0.670)
  Differentiation     0.602      4.494    \<0.05   1.825     (1.046, 3.182)
  Fer                 0.674      5.530    \<0.05   1.962     (1.119, 3.439)
  LNM                 1.072      7.307    \<0.05   2.921     (1.343, 6.353)

![Survival curves of patients in the HLL group and NL group.](cbm-13-4-469-1){#Figure1}

Discussion {#s04}
==========

Currently, there are many controversies on the application of LND in ICC patients. According to the AJCC guidelines on ICC, ICC and combined hepatocellular intrahepatic cholangiocarcinoma (cHCC-ICC) are not partitioned. Tumor diameter has been reported to be closely related to LNM and vascular invasion^[@b4]^. This study set the boundary value of the maximum tumor diameter at 5 cm. According to some ICC guidelines, surgical excision is suitable for patients in AJCC stages I and II, whereas conservative treatment is suitable for patients in stages III and IV (IVa and IVb)^[@b5]^. Therefore, the stage I and II cases were classified into one group, and stage III and IV cases were classified into another group. The effect of surgical resection on the prognosis of ICC was then investigated. Univariate analysis showed that age, gender, AJCC stage, differentiation, Fer, CA19-9, and CEA levels, LNM, and LND significantly affected the prognosis of ICC patients. Multivariate analysis revealed that age, AJCC stage, differentiation, Fer, and LNM were independent risk factors of survival. This study found that hepatitis B was not an independent risk factor for the prognosis of ICC patients, which is consistent with the view of some researchers^[@b5]^. No study had reported that Fer is an independent risk factor for the survival of ICC patients. However, plasma Fer concentrations were reported to be closely related to the occurrence and development of HCC, breast cancer, and gastrointestinal tumors^[@b7]-[@b9]^. Additionally, some researchers posited that in male patients, excessively high or low preoperative Fer concentrations are an independent risk factor for hepatitis C in HCC^[@b7]^. In this study, only Fer had statistically significant effects on survival rate whereas Fer, gender, and hepatitis B were covariates, which varied from the results reported by some studies performed in China^[@b10]^. In this study, we found that the risk of death was 1.7 times higher for patients with high preoperative Fer concentrations than for patients with normal Fer levels.

This study analyzed the application of LND in ICC, although the results of multivariate analysis showed that LND was not an independent risk factor for ICC survival. A total of 104 cases were divided into the HLL, EHLL, and NL groups. Univariate analysis showed that LND significantly affected the prognosis of ICC patients (*P* \< 0.05). This finding coincides with a previous perspective that ICC patients without LNM do not benefit from routine LND^[@b11]^. Furthermore, this study observed some differences among groups. The EHLL group had considerably improved prognosis compared with the HLL group, as noted from the OS, although the difference between groups was not statistically significant. Moreover, 5 cases in the EHLL group (5/12) and 6 cases in the HLL group (6/21) exhibited lymph metastases. LNM had been confirmed to be rarely confined to the first lymph node, and has an apparent tendency for skip metastasis^[@b11]^. Therefore, we suspected that ICC patients will not benefit from lymphadenectomy when LNM is absent. However, systematic lymphadenectomy may improve the outcomes of ICC if we identify the location of lymphatic metastasis^[@b13]^. Some researchers recommend that ICC patients without LNM should not undergo routine LND, and extended systemic LND is not recommended for ICC patients with LNM^[@b14]^. Therefore, this study analyzed LND and LNM as covariates. The results showed that only the effects of LNM on the prognosis were significantly different. LND did not significantly improve the prognosis of some ICC patients. Therefore, establishing a comprehensive, clear, and standardized LND system for ICC is critical. Multivariate analysis revealed that LNM was an independent factor for ICC prognosis, which is consistent with most research perspectives^[@b15],[@b16]^. Li et al.^[@b11]^ found that the ligamentum hepatoduodenale is the most common LNM site in ICC. In this study, 11 cases exhibited ICC in LNM, including 5 cases in zone 12, 5 cases in zone 8, 2 cases in zone 13, and 1 case in the retroperitoneum. Hence, the results suggested that zones 12 and 8 are the most common LNM sites.

Some shortcomings of this study must be acknowledged. First, the study performed retrospective analyses, and some clinical data may not be reliable. Several reports showed that vascular invasion and tumor number are independent prognostic factors^[@b16]^, which contradict our results. This discrepancy possibly resulted from the inaccuracy of some clinical information, selective bias of the treatment, or insufficient sample size. Some previous studies identified CEA and CA19-9 as prognostic factors for ICC, a conclusion not verified by this study^[@b15],[@b16]^. This incongruity might have resulted from the insufficient sample size, such that individual differences may have affected the result.

Moreover, this study collected cases that were in relatively early stages of ICC progression, and the majority of the AJCC stage I and II cases have increased in recent years. Therefore, the median survival time (34 months) in our study was higher than in some reports^[@b17],[@b18]^. In conclusion, we recommend that ICC patients without or with uncertain LNM should not undergo routine LND, but that ICC patients with LNM should undergo LND. A comprehensive, clear, and standardized LND system for early-stage ICC must be established.

Conflict of interest statement {#s05}
==============================

No potential conflicts of interest are disclosed.
